Cite
MLA Citation
Saira Sheikh et al.. “LB0012 HEADLINE RESULTS FOR A PHASE 4, 52-WEEK, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS ADVERSE EVENTS OF SPECIAL INTEREST (AESI) IN ADULTS WITH ACTIVE, AUTOANTIBODY-POSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) RECEIVING BELIMUMAB.” Annals of the rheumatic diseases, vol. 78, n.d., p. 266. http://access.bl.uk/ark:/81055/vdc_100144715525.0x000057